NEW YORK, NY / ACCESSWIRE / August 5, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA)
Investors Affected : May 28, 2021 - May 24, 2022
A class action has commenced on behalf of certain shareholders in Verrica Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica's contract manufacturer produced a bulk solution for the Company's lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/verrica-pharmaceuticals-inc-loss-submission-form/?id=30617&from=1
Molecular Partners AG (NASDAQ:MOLN)
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
A class action has commenced on behalf of certain shareholders in Molecular Partners AG. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ('FDA') was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ('EUA'); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Shareholders may find more information at https://securitiesclasslaw.com/securities/moln-lawsuit-molecular-partners-loss-submission-form/?id=30617&from=1
Missfresh Limited (NASDAQ:MF)
This lawsuit is on behalf of persons who purchased or otherwise acquired Missfresh securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Missfresh's June 2021 initial public offering.
A class action has commenced on behalf of certain shareholders in Missfresh Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Missfresh provided false financial figures in its registration statement
and related prospectus issued in connection with the Company's June 2021 initial public offering; (2) Missfresh would need to amend its financial figures; (3) Missfresh, among other things, had lesser net revenues for the quarter ended March 31, 2021; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.
Shareholders may find more information at https://securitiesclasslaw.com/securities/missfresh-lawsuit-loss-submission-form/?id=30617&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE : The Gross Law Firm
View source version on accesswire.com: